Data Sheet (Cat.No.T9121)

TargetMol

AG-636

Chemical Properties



CAS No. : 1623416-31-8

Formula: C21H17N3O2

Molecular Weight: 343.38

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	AG-636 is a potent, reversible, and selective DHODH inhibitor with an IC50 of 17 nM and is orally active. It demonstrates strong anticancer effects.
Targets(IC50)	Dehydrogenase,DNA/RNA Synthesis
In vitro	AG-636, in cancer cell lines of hematologic versus solid tumor origin.?Differential AG-636 activity translated to the in vivo setting, with complete tumor regression observed in a lymphoma model
In vivo	AG-636 (10-100 mg/kg; oral gavage; twice daily; for 14 days) treatment significantly inhibits tumor growth in the OCILY19 DLBCL tumor xenograft model.

Solubility Information

Solubility	DMSO: 31.25 mg/mL (91.01 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Corn Oil: 2 mg/mL (5.82 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.9122 mL	14.5611 mL	29.1223 mL
5 mM	0.5824 mL	2.9122 mL	5.8245 mL
10 mM	0.2912 mL	1.4561 mL	2.9122 mL
50 mM	0.0582 mL	0.2912 mL	0.5824 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Gabrielle McDonald, et al. Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase. Mol Cancer Ther. 2020 Dec;19(12): 2502-2515.